| Dexcom is on track to achieve nearly 50% U.S. customer conversion to its G7 15-day continuous glucose monitoring (CGM) system. This rollout is also expanding internationally. | By Year-End 2026 | 2026-11-13 | 2026-12-31 | The widespread adoption of advanced CGM systems like Dexcom G7 is fundamental to the theme's focus on proactive health monitoring and continuous metabolic feedback. Increased conversion and international rollout signify broader consumer engagement with tools for managing metabolic health, supporting behavioral changes and disease-risk reduction. | Ticker | theme_composer | DXCM | 1 | 0.0005 | 1.18 | 1.0 | | 1.0 | 0.0581 | 2026-11-13 | False | 1 | 0.0056 | 0.6576 | theme_composer | Theme composer | | |
| Hims & Hers is awaiting the FDA's 'full and final rule-making' regarding certain peptide therapies, specifically BPC-157 and TB-500. This regulatory clarity will impact the commercialization of its Peptides+ offering. | Ongoing, timing uncertain | 2026-11-13 | 2027-12-31 | Regulatory clarity on peptides is crucial for the theme's emerging aging-biology interventions. It will define the market for new longevity-science exposures and directly impact HIMS's ability to expand its proactive health monitoring and treatment platform into this high-growth area. | Theme | theme_composer | HIMS | 1 | 3.6 | 1.18 | 0.85 | Regulatory/Policy | 1.35 | 487.458 | 2026-11-13 | False | 1 | 0.001 | 0.141 | theme_composer | Theme composer | | |
| European regulatory approval for Foundayo (chronic weight management and type 2 diabetes) following a positive CHMP opinion. | by year end | 2026-10-01 | 2026-12-31 | This approval is crucial for the anticipated global rollout of Foundayo in major markets in 2027, significantly expanding its international revenue potential. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_10dadbeb | 2026-10-29 |
| Readout of Foundayo Phase 3 trial in obstructive sleep apnea. | later this year | 2026-10-01 | 2026-12-31 | Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_48d9403d | 2026-08-05 |
| U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes. | later this year | 2026-10-01 | 2026-12-31 | This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_696cb569 | 2026-08-05 |
| Launch of Orforglipron in a few international markets (e.g., UAE). | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_cf82d1b5 | 2026-02-04 |
| FDA provides perspective on explicit rule-making for peptides, specifically TB-500 and BPC-157, following the comment period. | in the next couple of weeks | 2026-11-10 | 2026-11-24 | Regulatory clarity is essential for Hims & Hers to launch these specific peptides, which could significantly expand their peptide offering and market opportunity, aligning with the broader GLP-1 theme. | Theme | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_18421c70 | 2026-11-09 |
| Hims & Hers launches its Peptides+ offering, including sermorelin, glutathione, and NAD+, with clinician-led treatment plans and access to regular blood testing. | later this month | 2026-11-01 | 2026-11-30 | This expands the platform into a new, complex care category, leveraging their infrastructure and potentially driving new revenue streams and customer engagement in the longevity and wellness space. | Ticker | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_7869cc52 | 2026-11-09 |
| Hims & Hers will launch flexible multi-month subscriptions across its weight loss assortment and expand access to Lilly's GLP-1 medications, Zepbound and Foundayo. | ahead of the new year | 2026-10-01 | 2026-12-31 | This broadens treatment options and improves pricing flexibility, potentially increasing customer acquisition, retention, and market share in the high-growth metabolic health category. | Ticker | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_d8f2182b | 2026-11-09 |
| Hims & Hers anticipates its AI-native experience will reach nearly 100% of weight loss subscribers. | before the end of the year | 2026-10-01 | 2026-12-31 | This is expected to drive higher engagement, better adherence, and improved customer satisfaction, leading to stronger retention and potentially lower churn. | Ticker | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_aa060124 | 2026-11-09 |
| Potential Medicare coverage expansion for Libre Continuous Glucose Monitoring (CGM) for Type 2 non-insulin users in the US. | in the fall | 2026-09-01 | 2026-11-30 | This could unlock a multibillion-dollar opportunity by accelerating commercial insurance coverage and reaching approximately 10 million Medicare beneficiaries, significantly boosting CGM sales. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_79370e41 | 2026-07-16 |
| FDA approval and US launch of Amulet 360 Left Atrial Appendage (LAA) device. | by year-end 2026 | 2026-10-01 | 2026-12-31 | This device is designed to help reduce the risk of stroke in patients with AFib and is expected to reignite growth and capture market share in the LAA closure market. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_30e24e43 | 2026-10-21 |
| Broad U.S. launch of TactiFlex Duo catheter. | starting in the fourth quarter | 2026-10-01 | 2026-12-31 | This catheter enables physicians to seamlessly switch between using RF and PFA energy during a procedure, which is expected to drive adoption and market share in electrophysiology. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_7cc559f2 | 2026-10-21 |
| Launch of Volt PFA catheter in Japan. | sometime in Q4 | 2026-10-01 | 2026-12-31 | This launch is expected to turn Japan from a headwind to a tailwind for the electrophysiology business, contributing to international growth acceleration. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_8bb43b0e | 2026-10-21 |
| Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | | | | | | | | | | | | | | | earnings_transcript | AMGN (ticker) | AMGN_fe4d51bf | 2026-02-03 |
| CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings. | Theme | | | | | | | | | | | | | | | earnings_transcript | DXCM (ticker) | DXCM_80554779 | 2026-07-30 |
| CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data. | before the end of this year | 2026-08-07 | 2026-12-31 | This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers. | Ticker | | | | | | | | | | | | | | | earnings_transcript | DXCM (ticker) | DXCM_e0606eaf | 2026-07-30 |
| Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system. | by year end | 2026-10-01 | 2026-12-31 | This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins. | Ticker | | | | | | | | | | | | | | | earnings_transcript | DXCM (ticker) | DXCM_b887655c | 2026-07-30 |
| Clinical launch of Reveal Ultra, the newest addition to Guardant Health's oncology portfolio. | before year-end | 2026-11-05 | 2026-12-31 | Reveal Ultra is expected to demonstrate market-leading sensitivity in minimal residual disease (MRD) detection, potentially setting a new performance bar and unlocking a significant new growth opportunity for the oncology business. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GH (ticker) | GH_4a8220c9 | 2026-11-05 |
| Guardant Health plans to launch Reveal Ultra, which is anticipated to be the most sensitive tumor-informed MRD test. | later this year | 2026-10-01 | 2026-12-31 | This new product launch is expected to redefine sensitivity in the tumor-informed MRD space, enhancing Guardant Health's competitive position and driving further volume growth in the MRD market. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GH (ticker) | GH_707b8be0 | 2026-07-30 |
| Second readout from the ATLAS-UC trial for tulisokibart in moderately to severely active ulcerative colitis. | second half of 2026 | 2026-09-01 | 2026-12-31 | This readout, combined with the earlier induction study, will form the basis of a regulatory filing, reinforcing confidence in the program's potential and expanding Merck's immunology portfolio. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MRK (ticker) | MRK_bcd577c2 | 2026-08-04 |
| Sprouts Farmers Market expects a one-time year-over-year gross margin benefit in the fourth quarter of 2026. | fourth quarter | 2026-10-01 | 2026-12-31 | This benefit is due to cycling an easier shrink comparison and the full-year impact of loyalty program changes (from $2 to $1), which is expected to slightly increase gross margins. | Ticker | | | | | | | | | | | | | | | earnings_transcript | SFM (ticker) | SFM_c0b54a88 | 2026-07-29 |
| Sequential comparable store sales improvement and return to long-term financial algorithm | late in the year | 2026-10-01 | 2026-12-31 | Management expects comps to rebound in the second half of 2026 as they lap easier comparisons and benefit from loyalty initiatives. Failure to show this improvement would suggest structural issues with traffic or a more severe consumer downturn. | Ticker | | | | | | | | | | | | | | | | SFM (ticker) | SFM_c3aa9cfe | 2026-02-19 |
| Execution of at least $300 million in share repurchases | in 2026 | 2026-02-19 | 2026-12-31 | This capital allocation plan is baked into the EPS guidance; a failure to execute the full amount due to cash flow constraints or alternative capital needs would negatively impact EPS growth and signal a shift in management's outlook. | Ticker | | | | | | | | | | | | | | | | SFM (ticker) | SFM_510092a2 | 2026-02-19 |
| U.S. launch of Libre Duo, the world's first dual glucose ketone biowearable sensor. | in December | 2026-12-01 | 2026-12-31 | This product allows people with diabetes to monitor ketones without traditional blood or urine tests, offering a new growth driver for the diabetes care business. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_6009f906 | 2026-10-21 |
| Resumption of the legacy Illumina royalty payments. | late December 2026 | 2026-12-01 | 2026-12-31 | This will negatively impact gross margins, with the full effect observed in Q1 2027, affecting the company's profitability. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GRAL (ticker) | GRAL_4b5b6dac | 2026-11-04 |
| Eli Lilly's Innovation Day will provide updates on its pipeline, including next-generation incretins like retatrutide and Olora-TZP, and other therapeutic areas. | December 7, 2026 | 2026-12-07 | 2026-12-07 | Lilly's pipeline updates are highly relevant to the theme's focus on advances in obesity medicine and aging-biology research. Positive data or new development plans for next-generation cardiometabolic therapies could significantly expand clinically supported interventions aimed at delaying chronic disease and preserving physical function. | Ticker | theme_composer | LLY | 1 | 5.88 | 1.18 | 1.05 | | 1.0 | 728.532 | 2026-11-13 | False | 1 | 0.2485 | 30.7951 | theme_composer | Theme composer | | |
| Lilly Innovation Day. | December 7th | 2026-12-07 | 2026-12-07 | This event is expected to provide more detailed insights into Lilly's pipeline, potentially revealing new material information about future growth drivers and strategic priorities. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_a24ab55b | 2026-10-29 |
| Impact of the 53rd week in the fiscal 2026 calendar | end of the fourth quarter | 2026-12-28 | 2027-01-03 | The extra week is expected to contribute approximately $200 million in sales and $0.21 in diluted EPS. This creates a non-comparable financial year that could skew year-over-year growth metrics and investor sentiment if not properly adjusted. | Ticker | | | | | | | | | | | | | | | | SFM (ticker) | SFM_44566cb6 | 2026-02-19 |
| GRAIL's Galleri multi-cancer early detection test is anticipated to receive FDA Premarket Approval (PMA). This approval is crucial for establishing Galleri as the 'gold standard' MCED and unlocking broader payer and employer adoption. | Early Q1 2027 | 2027-01-01 | 2027-03-31 | FDA approval for Galleri is a pivotal moment for the theme, as it validates population-level cancer screening and shifts healthcare towards earlier diagnosis and disease-risk reduction. It will likely create a bifurcated market, significantly impacting GRAL's market access and potentially influencing the competitive landscape for other early detection players. | Theme | theme_composer | GRAL, GH, ABT | 3 | 0.0063 | 1.18 | 1.0 | Regulatory/Policy | 1.35 | 0.9964 | 2026-11-13 | False | 2 | 0.448 | 71.3588 | theme_composer | Theme composer | | |
| Myriad Genetics anticipates securing reimbursement for its Precise MRD (Minimal Residual Disease) test in breast cancer. This will expand the test's commercial availability and adoption in recurrence monitoring. | First Half 2027 | 2027-01-01 | 2027-06-30 | This catalyst is important for the theme's focus on earlier diagnosis and disease-risk reduction by enabling more precise monitoring of cancer recurrence. Successful reimbursement for Precise MRD will drive revenue growth for MYGN and demonstrate progress in integrating advanced diagnostics into standard care pathways. | Theme | theme_composer | MYGN | 2 | 0.0 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.0019 | 2026-11-13 | False | 2 | 0.2001 | 29.329 | theme_composer | Theme composer | | |
| U.S. regulatory submission (BLA pathway) for retatrutide. | Q1 2027 | 2027-01-01 | 2027-03-31 | This submission is a critical step towards bringing the highly efficacious triple agonist, retatrutide, to market, potentially solidifying Lilly's leadership in cardiometabolic health with a drug demonstrating unprecedented weight loss. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_a075099b | 2026-10-29 |
| Significant U.S. payer formulary coverage for Libre goes into effect. | January 1 | 2027-01-01 | 2027-01-01 | This expanded coverage is expected to be a nice growth driver for the diabetes business in the coming year. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_c375ff52 | 2026-10-21 |
| CMS system update to process claims for the new Guardant360 Liquid CDx billing code. | January 2027 | 2027-01-01 | 2027-01-31 | This update will enable CMS to process claims for Guardant360 Liquid CDx, resolving a temporary delay and allowing Guardant Health to receive an estimated $10 million to $15 million in payments deferred from the second half of 2026, improving cash flow. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GH (ticker) | GH_f1eab5ab | 2026-11-05 |
| Receipt of ADLT (Advanced Diagnostic Laboratory Test) designation for Guardant360 Liquid CDx. | in the first half of 2027 | 2027-01-01 | 2027-06-30 | ADLT designation is expected to lead to an uplift in the average selling price (ASP) for Guardant360 Liquid CDx towards the Medicare price of $8,455, significantly improving reimbursement and gross margins. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GH (ticker) | GH_5318cd0f | 2026-11-05 |
| Guardant Health plans to offer widespread availability of Guardant360 Liquid CDx to U.S. customers. | following ADLT designation | 2027-01-01 | 2027-06-30 | This commercial rollout, following ADLT designation, will drive greater adoption of the test, simplify the therapy selection portfolio, and contribute to oncology volume growth. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GH (ticker) | GH_8850e4c8 | 2026-07-30 |
| Guardant Health remains on track to obtain ADLT designation for Guardant360 Liquid CDx. | first half of 2027 | 2027-01-01 | 2027-06-30 | This designation is expected to lead to an immediate increase in the average selling price (ASP) for Guardant360, improving gross margins and potentially accelerating the company's timeline to cash flow breakeven. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GH (ticker) | GH_4fe268e1 | 2026-07-30 |
| FDA final decision on the premarket approval (PMA) application for Galleri. | by early Q1 of 2027 | 2027-01-01 | 2027-03-31 | This is a pivotal catalyst expected to create a market bifurcation, establish Galleri as the gold standard MCED, and unlock broader payer and employer adoption, serving as the gateway for Medicare coverage. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GRAL (ticker) | GRAL_ea568ad2 | 2026-11-04 |
| FDA approval of the Galleri multi-cancer early detection test following its Premarket Approval (PMA) application. | in the first part of 2027 | 2027-01-01 | 2027-06-30 | FDA approval would provide critical regulatory validation, de-risk the technology, and pave the way for broader commercialization, payer coverage, and physician adoption. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GRAL (ticker) | GRAL_1d85fec4 | 2026-08-05 |
| Closing of the definitive agreement to sell Myriad's Prenatal Health business to Labcorp. | by early 2027, with an outside date of Feb 19, 2027 | 2027-01-01 | 2027-02-19 | This transformational transaction is expected to significantly improve Myriad's financial profile, including revenue growth, profitability, and liquidity, by allowing the company to focus on the Cancer Care Continuum. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MYGN (ticker) | MYGN_455de998 | 2026-11-04 |
| Full commercial launch of Precise MRD. | Q1 of 2027 | 2027-01-01 | 2027-03-31 | This represents the broader commercialization of the Precise MRD platform, significantly expanding its market reach and revenue potential across multiple cancer types. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MYGN (ticker) | MYGN_3a65a078 | 2026-05-05 |
| Site approvals and expansion into the Midwest and Northeast regions | 2027 and beyond | 2027-01-01 | 2027-12-31 | Laying the foundation for growth in these new territories is vital for the company's long-term expansion strategy. Successful site approvals and subsequent performance in these regions will determine if the Sprouts format is truly national in scale. | Ticker | | | | | | | | | | | | | | | | SFM (ticker) | SFM_5d6093a9 | 2026-02-19 |
| Transition to a more balanced quarterly store opening cadence | 2027 | 2027-01-01 | 2027-12-31 | A more balanced opening schedule in 2027 would reduce the heavy back-half pressure on the P&L seen in 2025 and 2026, potentially leading to more consistent quarterly earnings performance. | Ticker | | | | | | | | | | | | | | | | SFM (ticker) | SFM_7001504d | 2026-02-19 |
| Management target for the collective international business (inclusive of Eucalyptus) to reach break-even on an adjusted EBITDA basis within 12–18 months. | within 12 to 18 months | 2027-02-23 | 2027-08-23 | Achievement would validate international scaling playbook, reduce consolidated margin drag and accelerate path to 2030 EBITDA targets; failure to reach break-even would prolong international margin pressure and may require additional investment or slower expansion. | Ticker | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_8ce0db05 | 2026-02-23 |
| FDA approval of the PMA (Premarket Approval) application for Guardant360 Tissue. | sometime next year in terms of approval | 2027-11-05 | 2027-12-31 | A successful FDA approval would provide the highest level of regulatory clearance for Guardant360 Tissue, further supporting its rapid growth and potentially opening an ADLT pathway for the test, which could provide upside opportunity for reimbursement. | Ticker | | | | | | | | | | | | | | | earnings_transcript | GH (ticker) | GH_0d77252a | 2026-11-05 |